Targeted therapeutics in treatment of children and young adults with solid tumors: An expert survey and review of the literature

Klinische Padiatrie

Volumn 224, Issue 3, 2012, Pages 124-131

  Grunewald, T G P ^a   Greulich, N ^a   Kontny, U ^b   Fruhwald M ^c   Rutkowski, S ^d   Kordes, U ^d   Scheurlen, W ^e   Schmidt, W ^e   Stachel, D ^f   Metzler, M ^f   Mittler, U ^g   Graf, N ^h   Benesch, M ⁱ   Burdach, S ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e Cnopf'sche Kinderklinik   (Germany)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^h Children's Hospital Medical Center   (Germany)

ⁱ MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

biologicals; children; Delphi survey; solid tumor; targeted therapeutics

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DASATINIB; IMATINIB; IRINOTECAN; RAPAMYCIN; TEMOZOLOMIDE; VINBLASTINE;

ADULT; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEAT SENSATION; HUMAN; HYPERTENSION; INFECTION; KIDNEY FAILURE; LIVER FAILURE; MOLECULARLY TARGETED THERAPY; MUSCLE CRAMP; NEURILEMOMA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PROTEINURIA; RASH; REVIEW; RHABDOMYOSARCOMA; SIDE EFFECT; SOLID TUMOR;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; DELPHI TECHNIQUE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PIPERAZINES; PYRIMIDINES; SIROLIMUS; YOUNG ADULT;

EID: 84860563856     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0032-1301930     Document Type: Review

References (67)

1. Amato R J, Jac J, Giessinger S et al. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer: 2009; 115 2438 2446
2. Andersson M K, Aman P. Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. Cancer Cell Int: 2008; 8 1
3. Andr N, Verschuur A, Rossler J et al. Anti-angiogenic therapies for children with cancer. Curr Cancer Drug Targets: 2010; 10 879 889
4. Aplenc R, Blaney S M, Strauss L C et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. J Clin Oncol: 2011; 29 839 844
5. Augustine J J, Bodziak K A, Hricik D E et al. Use of sirolimus in solid organ transplantation. Drugs: 2007; 67 369 391 (Pubitemid 46425551)
6. Bailey H H, Mahoney M R, Ettinger D S et al. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer: 2006; 107 2462 2467 (Pubitemid 44748530)
7. Barr R D. Imatinib mesylate in children and adolescents with cancer. Pediatr Blood Cancer: 2010; 55 18 25
8. Baruchel S, Sharp J R, Bartels U et al. A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. Eur J Cancer: 2009; 45 2352 2359
9. Beaudry P, Nilsson M, Rioth M et al. Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther: 2008; 7 418 424 (Pubitemid 351302535)
10. Benesch M, Windelberg M, Sauseng W et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol: 2008; 19 807 813 (Pubitemid 351461055)
11. Berardi R, Onofri A, Pistelli M et al. Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. Core Evid: 2010; 5 61 76
12. Berger M, Krumbholz M, Dirksen U et al. Characterization of EWS-FLI1 fusion sites in Ewing sarcomas. Klin Padiatr: 2010; 222 03 10.1055/s-0030- 1254467
13. Blaney S M, Bernstein M, Neville K et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol: 2004; 22 4804 4809
14. Blum K A, Advani A, Fernandez L et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol: 2009; 147 507 514
15. Blumenschein G R Jr, Kies M S, Papadimitrakopoulou V A et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs: 2008; 26 81 87
16. Bond M, Bernstein M L, Pappo A et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer: 2008; 50 254 258
17. Burdach S, Jurgens H. High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT). Crit Rev Oncol Hematol: 2002; 41 169 189 (Pubitemid 34150128)
18. Calaminus G, Schneider D T, Weissbach L et al. Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor. Klin Padiatr: 2009; 221 136 140
19. Chugh R, Wathen J K, Maki R G et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol: 2009; 27 3148 3153
20. Cohen E E, Rosen L S, Vokes E E et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol: 2008; 26 4708 4713
21. Cook D J, Mulrow C D, Haynes R B et al. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med: 1997; 126 376 380 (Pubitemid 27102522)
22. Corbacioglu S. The RIST Strategy: Molecular-Based Multimodal Treatment Regimens in Pediatric Oncology. Klin Padiatr: 2010; 223 01, 10.1055/s-0030- 1270297
23. DuBois S G, Marina N, Glade-Bender J. Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer: 2010; 116 749 757
24. Duenas-Gonzalez A, Garca-Lpez P, Herrera L A et al. The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer: 2008; 7 82
25. Engel J B, Honig A, Schönhals T et al. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation. Eur J Obstet Gynecol Reprod Biol: 2008; 141 64 69
26. Eskens F A, Steeghs N, Verweij J et al. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. J Clin Oncol: 2009; 27 4169 4176
27. Esser R, Glienke W, Bochennek K et al. Detection of neuroblastoma cells during clinical follow up: advanced flow cytometry and rt-PCR for tyrosine hydroxylase using both conventional and real-time PCR. Klin Padiatr: 2011; 223 326 331
28. Fouladi M, Laningham F, Wu J et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol: 2007; 25 4806 4812 (Pubitemid 350086485)
29. Giles F, Fischer T, Cortes J et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res: 2006; 12 4628 4635 (Pubitemid 44297814)
30. Glade-Bender J L, Adamson P C, Reid J M et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol: 2008; 26 399 405 (Pubitemid 351171691)
31. Gore L, Rothenberg M L, O'Bryant C L et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res: 2008; 14 4517 4525
32. Greenberg J I, Cheresh D A. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opin Biol Ther: 2009; 9 1347 1356
33. Grunewald T G, Herbst S M, Heinze J et al. Understanding tumor heterogeneity as functional compartments - superorganisms revisited. J Transl Med: 2011; 9 79
34. Grunewald T G, Damke L, Maschan M et al. First report of effective and feasible treatment of multifocal lymphangiomatosis (Gorham-Stout) with bevacizumab in a child. Ann Oncol: 2010; 21 1733 1734
35. Hagenbuchner J, Ausserlechner M J, Porto V et al. The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression. J Biol Chem: 2010; 285 6904 6912
36. Hanzer M, Nebl A, Spendel S et al. Necrosis of a skin autograft after short-term treatment with sunitinib in a 14-year-old girl with metastatic alveolar soft part sarcoma of the thigh. Klin Padiatr: 2010; 222 184 186
37. Hero B, Kremens B, Klingebiel T et al. Does megatherapy contribute to survival in metastatic neuroblastoma? A retrospective analysis. German Cooperative Neuroblastoma Study Group. Klin Padiatr: 1997; 209 196 200 (Pubitemid 27328969)
38. Houghton P J. Development of Novel Therapy for Childhood Cancer: Promise and Challenges. Klin Padiatr: 2010; 223 01, 10.1055/s-0030-1270316
39. Jakacki R I, Hamilton M, Gilbertson R J et al. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol: 2008; 26 4921 4927
40. Janeway K A, Albritton K H, Van Den Abbeele A D et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer: 2009; 52 767 771
41. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ: 1995; 311 376 380
42. Khanna C, Helman L J. Molecular approaches in pediatric oncology. Annu Rev Med: 2006; 57 83 97 (Pubitemid 43261980)
43. Knapper S, Mills K I, Gilkes A F et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood: 2006; 108 3262 3270
44. Kumar S, Witzig T E, Rajkumar S V et al. Thalidomid: current role in the treatment of non-plasma cell malignancies. J Clin Oncol: 2004; 22 2477 2488 (Pubitemid 41115407)
45. Lampson L A. Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier. MAbs: 2011; 3 153 160
46. Lichtman M A. Battling the hematological malignancies: the 200 years' war. Oncologist: 2008; 13 126 138 (Pubitemid 351342576)
47. Maki R G, D'Adamo D R, Keohan M L et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol: 2009; 27 3133 3140
48. Miller A B, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer: 1981; 47 207 214 (Pubitemid 11167383)
49. Mita M M, Mita A C, Chu Q S et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol: 2008; 26 361 367 (Pubitemid 351171685)
50. Morabito A, Piccirillo M C, Falasconi F et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist: 2009; 14 378 390
51. Mühlethaler-Mottet A, Meier R, Flahaut M et al. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer: 2008; 7 55
52. Piekarz R L, Frye R, Turner M et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol: 2009; 27 5410 5417
53. Pollack I F, Stewart C F, Kocak M et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol: 2011; 13 290 297
54. Pressey J G, Wright J M, Geller J I et al. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer: 2010; 54 1035 1037
55. Ramalingam S S, Belani C P, Ruel C et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol: 2009; 4 97 101
56. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol: 2009; 27 3126 3132
57. Socinski M A, Langer C J, Huang J E et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol: 2009; 27 5255 5261
58. Spunt S L, Grupp S A, Vik T A et al. Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors. J Clin Oncol: 2011; 29 2933 2940
59. Staege M S, Hattenhorst U E, Neumann U E et al. DNA-microarrays as tools for the identification of tumor specific gene expression profiles: applications in tumor biology, diagnosis and therapy. Klin Padiatr: 2003; 215 135 139
60. Suttorp M, Claviez A, Bader P et al. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I. Klin Padiatr: 2009; 221 351 357
61. Vansteenkiste J, Van Cutsem E, Dumez H et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs: 2008; 26 483 488
62. Verneris M R, Arshi A, Edinger M et al. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res: 2005; 11 4561 4570 (Pubitemid 40825647)
63. Wilhelm S M, Dumas J, Adnane L et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer: 2011; 129 245 255
64. Zage P E, Graham T C, Zeng L et al. The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan. Cancer: 2011; 117 1321 1391
65. Zage P E, Zeng L, Palla S et al. A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid. Cancer: 2010; 116 2465 2475
66. Zebrack B J, Eshelman D A, Hudson M M et al. Health care for childhood cancer survivors: insights and perspectives from a Delphi panel of young adult survivors of childhood cancer. Cancer: 2004; 100 843 850 (Pubitemid 38176865)
67. Zhu A X, Stuart K, Blaszkowsky L S et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007 110 581 589